Neurologic Disorders

Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.

The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.

The use of low-dose naltrexone (LDN) to treat chronic fatigue syndrome was described in a recent case series published in BMJ Case Reports.

Treatment with vigabatrin carries the risk of permanent vision loss.

The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.

Neurological findings of myoclonus, ataxia, weakness, and autonomic instability differentiate EV-A71.

Mean five-year change lower in Expanded Disability Status Scale score with early intensive treatment

Neurodevelopmental outcomes at 5 years of age are equivalent after brief general anesthesia or awake-regional anesthesia in infancy.

Levetiracetam Injection, an antiepileptic, is indicated as adjunct therapy in patients aged ≥16 years with partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures, when oral administration is temporarily not feasible.